Animas announced that the Food and Drug Administration (FDA) has approved the OneTouch Vibe Plus Insulin Pump and Continuous Glucose Monitoring (CGM) System for the treatment of patients aged ≥2 years old with diabetes.

The OneTouch Vibe Plus is the first insulin pump to incorporate Dexcom G5 Mobile CGM technology, bringing together accurate insulin dosing technology with accurate CGM sensing technology. It also serves as the only integrated system approved for patients as young as 2 years old

Related Articles

This new system allows patients to see their glucose reading all the time via their pump or through their Dexcom G5 App on their smart phone, and allows delivery of exact amounts of insulin needed from the pump. Blood glucose readings are collected from the Dexcom sensor by the Dexcom G5 Transmitter and are then wirelessly sent to the compatible smart device and the Insulin Pump Screen. Both patients and caregivers can access CGM data at their convenience and can make necessary diabetes management decisions.

In addition, the glucose data can be shared with up to 5 people using the Dexcom Follow App. 

The launch date of the OneTouch Vibe Plus Insulin Pump and CGM System has not been determined at this time. 

For more information call (877) 937-7867 or visit